Natalie Vokes
UT MD Anderson · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Natalie Vokes as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:11 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07579221 · Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung CancerM.D. Anderson Cancer Center · recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph2NCT07133425 · A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung CancerM.D. Anderson Cancer Center · recruiting · Non-Small Cell Lung Cancer, ICI-refractory · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancerR01CA276178 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $658,360 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:11 UTC. The ranking covers the 200 most relevant of 2 PubMed records, and a shared surname and initials can bring in a namesake. All 2 on PubMed
- High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC.J Immunother Cancer · 202416 citationsRCR 1.7
- Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial.J Immunother Cancer · 20258 citationsRCR 1.7